The conversations this week are both related to endometriosis: on developing a new diagnosis tool with San Francisco company Endometrics’ CEO and co-founder Yana Aznavour, and on the developing a treatment side, it’s a discussion with Swedish company Gesynta Pharma’s chief medical officer and VP of clinical development, Eva Johnsson.
Times:
03:23 Endometrics
23:15 Gesynta Pharma
Endometrics
The diagnostic gap in women’s health is not just a clinical failure—it is a systemic one. For conditions like endometriosis, patients currently face an average diagnostic delay of nearly a decade, often requiring invasive surgical procedures just to receive an answer.
CEO and co-founder Yana Aznavour and her team at Endometrics are changing that narrative by unlocking the power of a biological resource that has been overlooked for decades: menstrual blood. By combining proprietary biobanking with advanced bioinformatics, the company has developed a non-invasive, at-home molecular diagnostic platform.
What begins with a validated test for endometriosis is expanding into a broader frontier of gynaecologic oncology and precision medicine, converting complex biological signals into clear, actionable clinical tools.
Backed by UC Berkeley SkyDeck and recognised by the NIH RADx ENDO Challenge, Aznavour, is bridging the gap between molecular biology and real-world patient impact.
Gesynta
Gesynta Pharma is a clinical-stage biotech company developing an innovative treatment for endometriosis. Its lead programme, vipoglanstat, is a novel oral, non-hormonal and non-opioid treatment candidate intended for long-term use, designed to target pain, inflammation and lesion development through selective inhibition of mPGES-1.
Preclinical studies have demonstrated strong and sustained pain relief, together with a 70% reduction in endometriotic lesions in an advanced disease model. Clinical studies have shown full target engagement, robust pharmacokinetics and a favourable safety and tolerability profile.
Gesynta is backed by an experienced team with extensive drug development expertise, leading scientific and clinical advisors, and an international investor base spanning European life science and US women’s health specialists.
The company recently completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com


